GO:0030293 transmembrane receptor protein tyrosine kinase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030293 defines a molecular function: binding to and stopping, preventing, or reducing the activity of a transmembrane receptor protein tyrosine kinase.
• This activity is central to regulating oncogenic signaling pathways such as ErbB/HER, FGFR, RET, and TAM receptors [1,2,8].
• Small-molecule inhibitors like entrectinib and butein exemplify exogenous modulators of this activity [4,5].
• Targeted protein degraders (e.g., for MERTK) represent a new way to achieve receptor tyrosine kinase inhibition.
• Dysregulation of this activity is implicated in cancers including thyroid, lung, and Ewing sarcoma [7,8].
• CRISPR knockout, knock-in, and overexpression models are essential to study the causal roles of these inhibitors.
Description
Transmembrane receptor protein tyrosine kinases (RTKs) are cell-surface receptors that transmit extracellular signals to control cell growth, differentiation, and survival. Their activity is tightly regulated, and when dysregulated, they drive numerous cancers and other diseases. The Gene Ontology (GO) term GO:0030293, transmembrane receptor protein tyrosine kinase inhibitor activity, describes a molecular function that directly opposes RTK signaling by binding to and reducing the activity of these receptors. This function is critical for maintaining normal cellular homeostasis and is a major target for therapeutic intervention. Understanding this activity helps researchers dissect signaling networks and develop targeted therapies.
transmembrane receptor protein tyrosine kinase inhibitor activity At A Glance
| GO ID | GO:0030293 |
|---|---|
| GO term | transmembrane receptor protein tyrosine kinase inhibitor activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Inhibition of transmembrane receptor protein tyrosine kinase activity |
| Definition | Binds to and stops, prevents or reduces the activity of a transmembrane receptor protein tyrosine kinase. |
| Related kinases | ErbB/HER, FGFR, RET, TAM (Axl, MERTK), TRK, ROS1, ALK |
| Disease relevance | Cancer, including thyroid, lung, and Ewing sarcoma |
| Therapeutic examples | Entrectinib, butein, targeted protein degraders |
What Is GO:0030293?
GO:0030293 is a molecular function term defined as the binding to and stopping, preventing, or reducing the activity of a transmembrane receptor protein tyrosine kinase. In other words, it is the activity of any protein or molecule that inhibits the enzymatic function of cell-surface receptor tyrosine kinases, thereby dampening downstream signaling cascades.
Why Is transmembrane receptor protein tyrosine kinase inhibitor activity Important in Cell Biology?
This activity is essential for controlling RTK signaling, which is frequently hyperactivated in cancer and other diseases [1,2]. Modulating this activity with inhibitors or degraders offers a powerful strategy to block oncogenic pathways, as demonstrated by approved drugs like entrectinib and emerging degraders for MERTK [3,5]. Studying GO:0030293 helps identify new therapeutic targets and understand resistance mechanisms.
• Regulates cell proliferation, survival, and differentiation by opposing RTK signaling.
• Dysregulation leads to various cancers, including breast, lung, thyroid, and sarcoma [2,7,8].
• Provides targets for small-molecule inhibitors such as entrectinib and butein [4,5].
• Enables development of targeted protein degraders for RTKs like MERTK.
• Critical for understanding tumor microenvironment interactions.
• Helps overcome drug resistance in RTK-driven cancers.
• Guides CRISPR-based functional genomics screens for RTK regulators.
• Supports precision medicine by matching inhibitors to specific RTK alterations.
• Informs combination therapies, e.g., with chemotherapy in Ewing sarcoma.
• Facilitates basic research on signal transduction and feedback loops.
What Happens During transmembrane receptor protein tyrosine kinase inhibitor activity?
Recognition and Binding to the Receptor Tyrosine Kinase
In simple terms: The inhibitor molecule finds and attaches to the receptor tyrosine kinase.
The first step in this activity is the specific binding of an inhibitor to a transmembrane receptor protein tyrosine kinase. This binding can occur at the extracellular ligand-binding domain, the transmembrane region, or the intracellular kinase domain, depending on the inhibitor. For example, small molecules like butein bind to the kinase domain and inhibit its activity. This interaction is highly selective and is the foundation for downstream inhibitory effects.
Inhibition of Kinase Activity
In simple terms: Once bound, the inhibitor stops the receptor from adding phosphate groups to itself or other proteins.
Upon binding, the inhibitor prevents the receptor tyrosine kinase from catalyzing the transfer of a phosphate group from ATP to tyrosine residues on substrate proteins. This can occur through competitive inhibition at the ATP-binding site, allosteric modulation, or steric hindrance [1,5]. For instance, entrectinib inhibits TRK, ROS1, and ALK kinases by occupying the ATP-binding pocket. This blockade halts autophosphorylation and downstream signaling.
Downstream Signaling Suppression
In simple terms: Blocking the receptor shuts down the signals it would normally send inside the cell.
Inhibition of the receptor tyrosine kinase leads to reduced phosphorylation of downstream adaptor proteins and decreased activation of pathways such as MAPK/ERK, PI3K/AKT, and JAK/STAT [1,7]. This results in altered gene expression, cell cycle arrest, or apoptosis. In Ewing sarcoma, co-targeting JAK1/STAT6/GAS6/TAM signaling enhances chemotherapy efficacy by suppressing these survival pathways.
Receptor Degradation or Downregulation
In simple terms: Some inhibitors cause the receptor to be destroyed or removed from the cell surface.
Certain inhibitors, such as heterobifunctional targeted protein degraders, not only block kinase activity but also induce degradation of the receptor tyrosine kinase. For example, degraders targeting MERTK and other TAM receptor paralogs lead to their ubiquitination and proteasomal degradation. This provides a more durable inhibition compared to reversible small molecules.
Key Genes Involved in GO:0030293 transmembrane receptor protein tyrosine kinase inhibitor activity
The following genes encode receptor tyrosine kinases or their inhibitors that are directly relevant to GO:0030293.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase of the ErbB family | Target of inhibitors in lung and breast cancer |
| ERBB2 | Receptor tyrosine kinase of the ErbB family | Target of inhibitors in breast and gastric cancer |
| FGFR1 | Fibroblast growth factor receptor | Inhibitor development for cancer and angiogenesis |
| FGFR2 | Fibroblast growth factor receptor | Inhibitor studies in cholangiocarcinoma and endometrial cancer |
| RET | Rearranged during transfection receptor tyrosine kinase | Inhibitors for thyroid and lung cancers |
| MERTK | TAM family receptor tyrosine kinase | Targeted degradation for cancer immunotherapy |
| AXL | TAM family receptor tyrosine kinase | Inhibitor research in cancer and fibrosis |
| NTRK1 | TRK family receptor tyrosine kinase | Target of entrectinib in solid tumors |
| NTRK2 | TRK family receptor tyrosine kinase | Target of entrectinib in solid tumors |
| NTRK3 | TRK family receptor tyrosine kinase | Target of entrectinib in solid tumors |
| ROS1 | Receptor tyrosine kinase | Target of entrectinib in lung cancer |
| ALK | Anaplastic lymphoma kinase | Target of entrectinib in lung cancer |
| GAS6 | Ligand for TAM receptors | Modulates TAM signaling in Ewing sarcoma |
| JAK1 | Janus kinase 1 | Co-target with TAM in Ewing sarcoma |
| STAT6 | Signal transducer and activator of transcription 6 | Co-target with TAM in Ewing sarcoma |
| PTK2 | Protein tyrosine kinase 2 (FAK) | Potential inhibitor target in cancer |
| SRC | Proto-oncogene tyrosine-protein kinase Src | Downstream of RTKs, inhibited by butein |
| PTPN11 | Protein tyrosine phosphatase non-receptor type 11 | Regulates RTK signaling, potential inhibitor |
How Is transmembrane receptor protein tyrosine kinase inhibitor activity Regulated?
The activity of transmembrane receptor protein tyrosine kinase inhibitors is regulated at multiple levels. Expression of endogenous inhibitor proteins can be controlled transcriptionally or post-translationally. For example, feedback loops involving phosphatases like PTPN11 can modulate RTK activity. Additionally, the efficacy of small-molecule inhibitors can be affected by mutations in the kinase domain, efflux pumps, or compensatory signaling pathways. Targeted protein degraders introduce a new layer of regulation by hijacking the ubiquitin-proteasome system.
transmembrane receptor protein tyrosine kinase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NTRK1 | Solid tumors with NTRK fusions | Knock-in of fusion gene in cell lines; drug sensitivity assays |
| RET | Thyroid and lung cancers | Point mutations in RET kinase domain; inhibitor testing |
| MERTK | Leukemia and solid tumors | Knockout or degradation via CRISPR; phagocytosis assays |
| AXL | Cancer and fibrosis | Overexpression and knockout models; inhibitor screening |
| FGFR2 | Cholangiocarcinoma | Knock-in of mutant FGFR2; organoid models |
Cancer
Dysregulated RTK signaling is a hallmark of many cancers. Inhibitors of RTKs are used clinically, such as entrectinib for NTRK, ROS1, and ALK fusion-positive cancers. In thyroid and lung cancers, RET inhibitors have shown efficacy. The development of resistance often necessitates novel inhibitors or degraders [3,6].
Ewing Sarcoma
In Ewing sarcoma, co-targeting JAK1/STAT6/GAS6/TAM signaling with chemotherapy improves efficacy, highlighting the importance of RTK inhibitor activity in this pediatric tumor.
Other Diseases
RTK inhibitors are also explored in fibrosis, neurodegeneration, and inflammatory diseases, where aberrant RTK signaling contributes to pathology [2,6].
From transmembrane receptor protein tyrosine kinase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of an RTK inhibitor gene increase RTK signaling? | CRISPR knockout of the inhibitor gene in cancer cell lines |
| How do point mutations in RTK affect inhibitor binding? | CRISPR point mutation knock-in of specific residues in the kinase domain |
| Can a fusion protein be targeted by inhibitors? | Knock-in of NTRK fusion constructs; drug response assays |
| What is the effect of RTK overexpression on cell proliferation? | CRISPR overexpression of wild-type or mutant RTK |
| Can targeted degradation of RTK be achieved? | Knock-in of degron tags or use of heterobifunctional degraders |
| What are the downstream signaling changes upon RTK inhibition? | Phosphoproteomics and RNA-seq after inhibitor treatment |
How to Study the transmembrane receptor protein tyrosine kinase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Identify RTK inhibitor genes in cancer cells |
| CRISPR knock-in | Specific mutations or tags | Study point mutations in RTK kinase domain |
| RNA-seq | Transcriptional changes | Assess downstream effects of RTK inhibition |
| Phosphoproteomics | Tyrosine phosphorylation | Map signaling pathways affected by inhibitors |
| Western blot | Protein expression and phosphorylation | Validate inhibitor efficacy |
| Cell viability assay | Proliferation and survival | Test drug sensitivity in knockout models |
| Xenograft | Tumor growth in vivo | Evaluate inhibitor efficacy and resistance |
| Targeted degradation | Protein stability | Assess degrader-induced RTK depletion |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes whose loss alters sensitivity to RTK inhibitors, revealing synthetic lethal interactions and resistance mechanisms [1,2].
Phosphoproteomics
Mass spectrometry-based phosphoproteomics quantifies changes in tyrosine phosphorylation upon RTK inhibition, providing a global view of signaling rewiring [5,7].
Targeted Protein Degradation
Heterobifunctional degraders can be used to acutely deplete RTKs, and their effects monitored by Western blotting and functional assays.
In Vivo Models
Xenograft and genetically engineered mouse models are used to test RTK inhibitors and degraders, assessing tumor growth and survival [5,8].
How CRISPR Can Be Used to Study GO:0030293 transmembrane receptor protein tyrosine kinase inhibitor activity
Knockout
CRISPR knockout of endogenous RTK inhibitor genes or the RTKs themselves can reveal their roles in signaling and disease. For example, knocking out MERTK in cancer cells can sensitize them to chemotherapy.
Point Mutation
Introducing point mutations in RTK genes via CRISPR can model clinical resistance mutations or validate inhibitor binding sites. This helps in understanding drug selectivity and resistance.
Knock-in
Knock-in of fusion genes (e.g., NTRK fusions) or reporter tags allows precise modeling of oncogenic drivers and testing of targeted inhibitors.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate RTK levels to study oncogenic signaling and screen for inhibitors.
How EDITGENE Supports transmembrane receptor protein tyrosine kinase inhibitor activity Research
Researchers studying transmembrane receptor protein tyrosine kinase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in signaling, disease, or drug response. EDITGENE provides comprehensive CRISPR services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for transmembrane receptor protein tyrosine kinase inhibitor activity research.
Frequently Asked Questions About transmembrane receptor protein tyrosine kinase inhibitor activity
What is GO:0030293?
GO:0030293 is a Gene Ontology molecular function term for transmembrane receptor protein tyrosine kinase inhibitor activity, which describes the binding to and inhibition of receptor tyrosine kinases.
What genes are involved in transmembrane receptor protein tyrosine kinase inhibitor activity?
Genes encoding RTKs such as EGFR, ERBB2, FGFR1, RET, MERTK, AXL, NTRK1/2/3, ROS1, and ALK are directly relevant, as well as their inhibitors [1,2,3,5,6,8].
How is transmembrane receptor protein tyrosine kinase inhibitor activity regulated?
It is regulated by expression of endogenous inhibitors, feedback phosphatases, and the ubiquitin-proteasome system for degraders [1,3].
What diseases are associated with this activity?
Cancers such as thyroid, lung, and Ewing sarcoma, as well as fibrosis and inflammatory diseases [2,5,7,8].
What are examples of inhibitors targeting this activity?
Entrectinib (targeting TRK, ROS1, ALK) and butein (a specific protein tyrosine kinase inhibitor) are examples [4,5].
How can CRISPR be used to study this activity?
CRISPR knockout, knock-in, and overexpression models allow functional dissection of RTK inhibitor genes and drug response [3,5].
What is the role of MERTK in this context?
MERTK is a TAM family RTK whose degradation by targeted protein degraders represents a novel way to inhibit its activity.
Why is this GO term important for cancer research?
Because hyperactive RTK signaling drives many cancers, and inhibiting it is a key therapeutic strategy [1,8].
What methods are used to measure this activity?
Phosphoproteomics, Western blot, cell viability assays, and CRISPR screens are commonly used [5,7].
Can EDITGENE help create models for this activity?
Yes, EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, and library screening services.
Conclusion
GO:0030293 transmembrane receptor protein tyrosine kinase inhibitor activity is a fundamental molecular function that counteracts RTK signaling. Its study is crucial for understanding cancer biology and developing targeted therapies. With CRISPR tools and EDITGENE's services, researchers can precisely model and interrogate this activity to accelerate drug discovery.
References
- 1. Roskoski R Jr. 2014. The ErbB/HER family of protein-tyrosine kinases and cancer.. Pharmacol Res 79:34-74 PMID: 24269963
- 2. Katoh M. 2016. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).. Int J Mol Med 38(1):3-15 PMID: 27245147
- 3. Gadiyar V et al.. 2023. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.. Front Immunol 14:1135373 PMID: 37545504
- 4. Yang EB et al.. 1998. Butein, a specific protein tyrosine kinase inhibitor.. Biochem Biophys Res Commun 245(2):435-8 PMID: 9571170
- 5. Drilon A et al.. 2017. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).. Cancer Discov 7(4):400-409 PMID: 28183697
- 6. Sun ZG et al.. 2019. Research Progress of Axl Inhibitors.. Curr Top Med Chem 19(15):1338-1349 PMID: 31218961
- 7. Yu L et al.. 2024. Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma.. Nat Commun 15(1):5292 PMID: 38906855
- 8. Roskoski R Jr et al.. 2018. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.. Pharmacol Res 128:1-17 PMID: 29284153
